A previous clinical study reported that HIF1α was significantly upregulated in bevacizumab resistant metastatic colorectal cancer, thus it is a potential biomarker of anti-angiogenesis resistance [25]. This evidence concerns the gene HIF1A and metastatic colorectal cancer.